Impact of nonalcoholic fatty liver disease on atrial fibrillation recurrence after catheter ablation: a prospective cohort study

Background Nonalcoholic fatty liver disease (NAFLD), prevalent in 25% globally, correlates with heightened cardiovascular risks. Retrospective studies suggest NAFLD increases post-ablation atrial arrhythmia recurrence, but prospective evidence is lacking. Methods This registered cohort study (ChiCTR2200059079) enrolled 106 AF ablation patients (53 NAFLD vs. 53 non-NAFLD). AF recurrence risk was assessed using multivariable Cox proportional hazards regression. NAFLD was diagnosed per American Association for the Study of Liver Diseases criteria, with fibrosis staged by FIB-4 (Fibrosis-4 index). Results NAFLD patients exhibited higher recurrence rates (49.1% vs. 24.5%, p = 0.022; annualized incidence: 48.1 vs. 24.0 per 100 person-years). Advanced fibrosis (FIB-4 > 1.30) amplified recurrence risk (71.4% vs. 34.4%, p = 0.024). Metabolic indices (BMI/glucose/lipids) did not independently predict outcomes. Conclusion NAFLD independently predicts AF recurrence post-ablation, with fibrosis severity stratifying risk. This underscores NAFLD management as a potential therapeutic target.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-03-13
DOI
https://doi.org/10.3389/fcvm.2026.1747145
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of nonalcoholic fatty liver disease on atrial fibrillation recurrence after catheter ablation: a prospective cohort study

Kezeng Gong, Feilong Zhang, XueHai Chen, Yunling Lin et al.
Frontiers in Cardiovascular Medicine
Liver Disease Diagnosis and Treatment
article

Impact of nonalcoholic fatty liver disease on atrial fibrillation recurrence after catheter ablation: a prospective cohort study

Kezeng Gong, Feilong Zhang, XueHai Chen, Yunling Lin, Tao Yi, Zhe Xu
article en

Abstract

Background Nonalcoholic fatty liver disease (NAFLD), prevalent in 25% globally, correlates with heightened cardiovascular risks. Retrospective studies suggest NAFLD increases post-ablation atrial arrhythmia recurrence, but prospective evidence is lacking. Methods This registered cohort study (ChiCTR2200059079) enrolled 106 AF ablation patients (53 NAFLD vs. 53 non-NAFLD). AF recurrence risk was assessed using multivariable Cox proportional hazards regression. NAFLD was diagnosed per American Association for the Study of Liver Diseases criteria, with fibrosis staged by FIB-4 (Fibrosis-4 index). Results NAFLD patients exhibited higher recurrence rates (49.1% vs. 24.5%, p = 0.022; annualized incidence: 48.1 vs. 24.0 per 100 person-years). Advanced fibrosis (FIB-4 > 1.30) amplified recurrence risk (71.4% vs. 34.4%, p = 0.024). Metabolic indices (BMI/glucose/lipids) did not independently predict outcomes. Conclusion NAFLD independently predicts AF recurrence post-ablation, with fibrosis severity stratifying risk. This underscores NAFLD management as a potential therapeutic target.

Frontiers in Cardiovascular MedicineVol. 13
Fujian Medical University (CN), Fujian Institute of Microbiology (CN), Fujian Business University (CN)
Natural Science Foundation of Fujian Province
Good health and well-being
Openalex Percentile: Top 25%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Impact of nonalcoholic fatty liver disease on atrial fibrillation recurrence after catheter ablation: a prospective cohort study — Kezeng Gong, Feilong Zhang, et al. · Frontiers in Cardiovascular Medicine (2026) | TGRS Research Map | TGRS